A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current Drugs

Phase 2Not Yet RecruitingNCT07838753

Kokilaben Dheerubhai Ambani Hospital and Research170 enrolled

Overview

The goal of this randomized comparative study (a study where participants are placed into groups by chance) is to find out if reducing treatment to androgen deprivation therapy (ADT)-a treatment that lowers testosterone-by itself works just as well as continuing the original combination of drugs. This study involves adult men with metastatic hormone-sensitive prostate cancer (prostate cancer that has spread to other parts of the body but still responds to hormone treatments) who have responded very well after 6 to 7 months of their initial two-drug or three-drug treatment. The main questions it aims to answer are: 1. Does reducing treatment to ADT alone work as well as the combination treatment at keeping the cancer from growing on imaging scans after 18 months, also known as radiographic progression-free survival (rPFS)? 2. Does reducing treatment to ADT alone work as well as the combination treatment at preventing a rise in prostate-specific antigen (PSA), known as PSA progression-free survival (PSA-PFS)? Researchers will compare a continuation group, which continues their initial two-drug or three-drug treatment, to a reduced-treatment group, which stops taking the androgen receptor pathway inhibitor (ARPI)-a drug that blocks the effects of hormones on cancer cells. Researchers want to see if reducing the treatment safely controls the cancer while lowering drug side effects and financial costs. Participants will: 1. Complete a 6- to 7-month initial period receiving a two-drug or three-drug treatment chosen by their doctor. 2. Have blood tests for PSA and testosterone, and undergo a specialized imaging scan called a prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) scan, to confirm the treatment is working very well before being assigned to a study group. 3. Stop taking the ARPI drug if assigned to the reduced-treatment group, or continue their current medications if assigned to the continuation group. 4. Go to check-up visits every 3 months for the first 24 months to complete physical exams, blood tests, and quality-of-life surveys. 5. Have a PSMA PET/CT scan every 6 months after being put into a group to check if the cancer has grown.

This phase 2 randomized comparative study investigates the de-escalation of systemic therapy for patients with metastatic hormone-sensitive prostate cancer (mHSPC) (STEPDOWNmHSPC i.e. Strategy for Therapy Escalation Pruning in metastatic Hormone Sensitive Prostate Cancer)who have achieved an optimal response to initial treatment. A. Background and Rationale: In India, 40-60% of patients diagnosed with prostate cancer present with metastatic disease, a significantly higher rate than the 5-10% observed in Western cohorts. While indefinite doublet or triplet therapies (combining androgen deprivation therapy \[ADT\], androgen receptor pathway inhibitors \[ARPI\], and sometimes docetaxel) are the standard of care, they cause substantial cumulative physical, metabolic, and financial toxicities. Because a significant sub-population of patients achieves a deep response to these therapies, this trial evaluates whether carefully selected patients can safely de-escalate to ADT monotherapy without compromising oncological outcomes. B. Study Objectives: 1. Primary Objective: To determine if de-escalation to ADT monotherapy is non-inferior to continuing doublet or triplet therapy regarding 18-month radiographic progression-free survival (rPFS) and PSA Progression-Free Survival (PSA-PFS). 2. Secondary Objectives: To compare overall survival, time to castration-resistant prostate cancer (CRPC), sustained complete PSMA PET responses at 12 and 24 months, quality of life (using EORTC QLQ-C30 i.e. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30), incidence of severe adverse events, and economic burden between the two arms. C. Study Design and Methodology: 1. Target Population: Adult men with histologically confirmed prostate adenocarcinoma, an ECOG (Eastern Co-operative Oncology Group) performance status of 0-2, and documented metastatic disease on PSMA PET/CT. 2. Run-In Phase: The study will initially enrol approximately 265 patients, who will undergo 6 to 7 months of standard doublet or triplet therapy. 3. Randomization: Following the run-in phase, patients who achieve an "optimal response"-defined as a serum PSA \< 0.2 ng/mL, castrate testosterone levels (\< 50 ng/dL), and a partial or complete response on PSMA PET/CT with no new lesions-will be randomized 1:1 into two arms. The trial targets 170 randomized patients (85 per arm) to account for an estimated 10% attrition rate. Arm A (Continuation): Patients will continue their initial ADT and ARPI regimen at the same doses. Arm B (De-escalation): Patients will discontinue the ARPI and continue with ADT monotherapy. D. Statistical Analysis: To establish non-inferiority, the study utilizes a 15% margin with 80% power and a one-sided alpha of 0.10. Radiographic progression-free survival will be estimated using the Kaplan-Meier method, and treatments will be compared using a stratified log-rank test and Cox proportional hazards regression based on randomization stratification factors. The primary analysis will be performed on both the Intention-To-Treat (ITT) and Per-Protocol (PP) populations, requiring consistent findings in both to declare non-inferiority.

Eligibility

Sex: MALEMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: Inclusion criteria for enrolment: 1. All patients of age group 18 to 80 years will be included 2. Patients who would voluntarily agree to sign informed consent form 3. Histologically confirmed adenocarcinoma of the prostate 4. Evidence of metastatic disease at diagnosis (de novo) or after definitive local therapy, documented on PSMA PET/CT 5. Intended to receive ADT plus an ARPI (abiraterone, enzalutamide, apalutamide or darolutamide) OR ADT plus ARPI plus docetaxel, as determined by the treating physician prior to enrolment 6. ECOG performance status 0-2 7. Adequate organ function: haemoglobin ≥ 9 g/dL; absolute neutrophil count ≥ 1.5 × 10⁹/L; platelets ≥ 100 × 10⁹/L; serum creatinine ≤ 1.5 × ULN or estimated GFR ≥ 45 mL/min; total bilirubin ≤ 1.5 × ULN; AST/ALT ≤ 2.5 × ULN 8. Life expectancy ≥ 12 months Criteria for randomization ("optimal responder"): 1. Completion of 6-7 months of protocol-defined doublet or triplet therapy without unplanned interruption \> 30 days 2. Serum PSA \< 0.2 ng/mL at re-staging 3. Serum testosterone at castrate level (\< 50 ng/dL) 4. PSMA PET/CT demonstrating partial or complete response as per PPP criteria: (i) no new PSMA-avid lesions; (ii) \> 30 % decrease in total PSMA tumour volume compared with baseline; and (iii) no progression at existing sites 5. ECOG 0-2 at re-staging 6. Adequate organ function (as at baseline) 7. Ongoing willingness to participate and to comply with randomized treatment Exclusion Criteria: Exclusion criteria for enrolment: 1. Known small-cell, neuroendocrine or predominantly sarcomatoid histology 2. Prior systemic therapy for prostate cancer other than ≤ 90 days of ADT (± a short course of first-generation anti-androgen for flare prevention) at enrolment 3. Prior treatment with any ARPI, docetaxel, cabazitaxel, Ra-223 or 177Lu-PSMA 4. Uncontrolled hypertension (systolic ≥ 160 mm Hg or diastolic ≥ 100 mm Hg despite therapy), history of seizures or predisposing conditions (for enzalutamide candidates), unstable cardiac disease, recent myocardial infarction or stroke within 6 months 5. Known active second malignancy requiring systemic therapy (except adequately treated non-melanoma skin cancer) 6. Active uncontrolled infection including HIV, hepatitis B or C with detectable viral load, or tuberculosis on active treatment 7. Any contraindication to the chosen ARPI, docetaxel or ADT per respective product labels 8. Psychiatric or cognitive disorder limiting capacity to consent or comply with protocol Exclusion criteria at randomization: 1. Serum PSA ≥ 0.2 ng/mL or any PSA rise above nadir of ≥ 25 % 2. Any new lesion on PSMA PET or conventional imaging 3. Progression at existing sites per PCWG4 or PPP 4. Testosterone ≥ 50 ng/dL (non-castrate) 5. Development of symptomatic disease (e.g. new bone pain requiring opioid therapy, cord compression, pathological fracture) 6. Grade ≥ 3 ongoing toxicities attributable to current therapy that precludes continuation 7. Withdrawal of consent

Outcomes

Primary Outcomes

18-month radiographic progression-free survival (rPFS)

Time from randomization to the earliest of: radiographic progression per PCWG4 on PSMA PET; unequivocal progression on PSMA PET (≥ 2 new lesions or PPP progression); or death from any cause. Patients without an event at 18 months are censored at last assessment.

Time frame: Assessed from the date of randomization up to 18 months, with routine PSMA PET/CT imaging conducted every 6 months (patients without an event at 18 months are censored at their last assessment)

PSA progression-free survival

Time from randomization to confirmed PSA progression per PCWG4 (≥ 25 % rise and ≥ 2 ng/mL above nadir, confirmed ≥ 3 weeks later), or death

Time frame: Assessed from the time of randomization until confirmed PSA progression or death, evaluated every 3 months for the first 24 months and every 6 months thereafter, through the total follow-up period (minimum 24 months post-randomization; up to 60 months)

Secondary Outcomes

Time to CRPC

Time from randomization to castration resistance per EAU/PCWG4 definition

Time frame: Through study completion, an average of 5 years

Overall survival

Time from randomization to death from any cause

Time frame: Assessed continuously from the date of randomization until death from any cause, with survival follow-up conducted every 6 months until study conclusion (up to approximately 60 months total duration)

PSMA PET complete response

Proportion with sustained PSMA PET complete response per modified PPP/RECIP at 12 and 24 months

Time frame: From randomization, at 12 and 24 months

Change in Quality of Life Measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

Change from baseline in health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The EORTC QLQ-C30 includes a Global Health Status/Quality of Life (GHS/QoL) scale, functional scales, and symptom scales/items. All scales and single items range from 0 to 100. For the Global Health Status and functional scales, a higher score represents a higher/better level of functioning and quality of life. For symptom scales and items, a higher score represents a higher/worse level of symptoms or problems.

Time frame: Assessed via changes from baseline, measured at screening, at the 6-7 month re-staging/randomization visit, and every 3 months post-randomization for the first 24 months

Incidence of Toxicity

Incidence of grade ≥3 AEs per CTCAE (Common Terminology Criteria for Adverse Events) v5.0

Time frame: Monitored continuously and evaluated at every scheduled visit (every 3 months during the 6-7 month run-in phase, every 3 months for the first 24 months post-randomization, and every 6 months (up to 60 months)

A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current Drugs

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts